Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 33.1% in October

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 165,900 shares, a growth of 33.1% from the September 30th total of 124,600 shares. Based on an average daily volume of 46,700 shares, the short-interest ratio is presently 3.6 days. Currently, 3.4% of the company’s stock are sold short.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ:BCLI traded up $0.07 during midday trading on Friday, hitting $1.96. 49,745 shares of the company’s stock were exchanged, compared to its average volume of 52,560. Brainstorm Cell Therapeutics has a 12 month low of $1.88 and a 12 month high of $11.89. The company has a market cap of $137.33 million, a PE ratio of -6.12 and a beta of 0.33. The stock has a 50 day moving average price of $3.50 and a 200-day moving average price of $5.38.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.60). During the same period in the prior year, the business posted ($4.05) earnings per share. On average, analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 14.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. StockNews.com began coverage on Brainstorm Cell Therapeutics in a research note on Wednesday, October 9th. They issued a “hold” rating for the company. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.